Equities

Curative Biotechnology Inc

CUBT:PKC

Curative Biotechnology Inc

Actions
  • Price (USD)0.019
  • Today's Change0.000 / -1.04%
  • Shares traded52.50k
  • 1 Year change+42.86%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 19:16 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.02m
  • Incorporated2007
  • Employees4.00
  • Location
    Curative Biotechnology Inc1825 Nw Corporate Blvd., Suite 110BOCA RATON 33431United StatesUSA
  • Phone+1 (561) 907-8990
  • Websitehttps://curativebiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Allied Corp21.51k-9.00m16.03m--------745.29-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Galecto Inc0.00-30.83m16.48m13.00--0.5854-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Pharmacyte Biotech Inc0.00-14.82m16.57m2.00--0.5323-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Talis Biomedical Corp989.00k-57.21m16.76m99.00--0.2958--16.95-31.44-31.440.543431.110.0092--14.879,989.90-53.08-68.18-58.71-74.2297.27---5,784.73-1,615.96----0.00---55.65-2.2445.13---1.83--
Nascent Biotech Inc0.00-2.09m16.80m----550.02-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Curative Biotechnology Inc0.00-6.02m17.16m4.00---------0.0105-0.01050.00-0.00180.00----0.00-339.98-----------------5.51---------302.92------
Kintara Therapeutics Inc0.00-9.51m17.17m2.00---------4.08-4.080.000.10710.00----0.00-131.55-220.94-185.60-329.97------------0.00------40.24--78.93--
Alaunos Therapeutics Inc6.00k-26.77m17.45m1.00--3.64--2,908.94-1.67-1.670.00040.29960.0002--12.006,000.00-97.94-74.83-147.22-89.57-----446,233.30-10,508.06---19.250.00---99.83-49.086.86---15.56--
GlycoMimetics Inc10.00k-37.28m17.47m35.00--0.6041--1,746.99-0.5791-0.57910.00020.44860.0002--0.0581285.71-72.29-43.60-81.84-47.82-----372,767.40-2,243.52----0.00---86.67--20.97---29.82--
Talphera Inc651.00k-14.31m17.50m15.00--1.07--26.89-0.8945-0.88630.03680.96120.0237----43,400.00-51.96-22.60-67.70-28.55-----2,197.39-714.87----0.00-----21.26-119.16---34.33--
Aytu Biopharma Inc93.76m-13.68m17.54m150.00--0.5699--0.1871-2.65-2.6518.215.530.67922.422.93625,053.30-9.91-33.56-25.58-52.8165.3256.89-14.60-73.810.69230.2160.352--11.1096.5684.33------
VBI Vaccines Inc9.41m-83.99m17.57m131.00------1.87-6.93-6.930.4818-0.21660.09231.4037.0571,839.70-81.40-46.58-171.57-58.62-24.06-277.46-881.79-2,755.980.2116-1.601.13--702.4020.9417.18---32.07--
Minerva Neurosciences Inc0.00-31.60m17.83m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Lumos Pharma Inc1.53m-37.13m18.26m33.00--1.05--11.98-4.59-4.590.18862.150.0332--8.0146,212.12-80.89-29.78-90.15-32.32-----2,434.69-2,937.61----0.00--34.67-30.31-9.57------
Synlogic Inc3.21m-73.22m18.26m6.00--1.36--5.70-10.62-10.620.45761.150.0495----534,166.70-113.09-40.57-134.57-43.82-----2,284.68-3,245.93----0.00008--185.685.9913.40---48.05--
Data as of May 31 2024. Currency figures normalised to Curative Biotechnology Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.